These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 16167063)
1. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. El-Zawahry A; Lu P; White SJ; Voelkel-Johnson C Cancer Gene Ther; 2006 Mar; 13(3):281-9. PubMed ID: 16167063 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. VanOosten RL; Earel JK; Griffith TS Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549 [TBL] [Abstract][Full Text] [Related]
4. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422 [TBL] [Abstract][Full Text] [Related]
5. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Zhang L; Gu J; Lin T; Huang X; Roth JA; Fang B Gene Ther; 2002 Sep; 9(18):1262-70. PubMed ID: 12215894 [TBL] [Abstract][Full Text] [Related]
7. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Vanoosten RL; Moore JM; Ludwig AT; Griffith TS Mol Ther; 2005 Apr; 11(4):542-52. PubMed ID: 15771957 [TBL] [Abstract][Full Text] [Related]
8. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649 [TBL] [Abstract][Full Text] [Related]
10. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R; Bedi A Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Zhang L; Fang B Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937 [TBL] [Abstract][Full Text] [Related]
12. High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. Jönsson G; Paulie S; Grandien A Anticancer Res; 2003; 23(2B):1213-8. PubMed ID: 12820373 [TBL] [Abstract][Full Text] [Related]
13. NFkappaB-mediated upregulation of bcl-xl restrains TRAIL-mediated apoptosis in murine viral hepatitis. Zender L; Hütker S; Mundt B; Waltemathe M; Klein C; Trautwein C; Malek NP; Manns MP; Kühnel F; Kubicka S Hepatology; 2005 Feb; 41(2):280-8. PubMed ID: 15660391 [TBL] [Abstract][Full Text] [Related]
14. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Voelkel-Johnson C; King DL; Norris JS Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034 [TBL] [Abstract][Full Text] [Related]
15. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Huerta-Yepez S; Vega M; Jazirehi A; Garban H; Hongo F; Cheng G; Bonavida B Oncogene; 2004 Jun; 23(29):4993-5003. PubMed ID: 15048072 [TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Sachs MD; Ramamurthy M; Poel Hv; Wickham TJ; Lamfers M; Gerritsen W; Chowdhury W; Li Y; Schoenberg MP; Rodriguez R Cancer Gene Ther; 2004 Jul; 11(7):477-86. PubMed ID: 15118762 [TBL] [Abstract][Full Text] [Related]
18. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667 [TBL] [Abstract][Full Text] [Related]
19. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296 [TBL] [Abstract][Full Text] [Related]
20. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Aggarwal BB; Bhardwaj U; Takada Y Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]